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Objective: Controversy surrounds the topic of transfusion policy after noncardiac operations. This study assessed the
combined impact of postoperative nadir hemoglobin (nHb) levels and blood transfusion on adverse events after open
surgical intervention in patients who undergo operative intervention for atherosclerotic vascular disease.
Methods: Consecutive patients who underwent peripheral arterial disease (PAD)-related operations were balanced on
baseline characteristics by inverse weighting on propensity score calculated as their probability to have nHb greater than
10 gm/dL on the basis of operation type, demographics, and comorbidities, including the revised cardiac risk index.
A multivariate generalized estimating equation analysis was performed to investigate associations between nHb, trans-
fusion, and a composite outcome of perioperative death and myocardial infarction. Logistic and Cox proportional hazards
regressions were used to assess the impact of nHb and transfusion on respiratory and wound complications; and
a composite end point (CE) of death, myocardial infarction during a 2-year follow-up. Level of statistical signiﬁcance was
set at alpha of 0.0125 to adjust for the increased probability of type I error attributable to multiple comparisons.
Results: The analysis cohort included 880 patients (1074 operations). After adjusting for nHb level, the number of units
transfusedwasnot associatedwith theperioperativeoccurrenceof theCE(odds ratio [OR],1.13;P[ .025).Adjusted for the
number of units transfused, nHb had no impact on the perioperative CE (OR, 0.62; P[ .22). An interaction term between
transfusion and nHb level remained nonsigniﬁcant (P[ .312), indicating that the impact of blood transfusionwas the same
regardless of the nHb level. Perioperative respiratory complications were more likely in patients receiving transfusions
(OR, 1.22; P[ .009), and perioperative wound infections were less common in patients with nHb >10 gm/dL (OR, 0.65;
P[ .01). During an average follow-up of 24 months, transfused patients were more likely to develop the CE (hazard ratio
[HR], 1.15,P[ .009), whereas nHb level did not impact the long-term adverse event rate (HR, 0.78;P[ .373). The above
associations persisted even after adjusting the Cox regression model for the occurrence of perioperative cardiac events.
Conclusions: Although nHb less than 10 gm/dL is not associated with death or ACS after PAD-related operations,
maintaining nHb greater than 10 gm/dL appears to decrease the risk of wound infection. Blood transfusion is associated
with increased risk of perioperative respiratory complications. Until a randomized trial settles this issue deﬁnitively,
a restrictive transfusion strategy is justiﬁed in patients undergoing operations for atherosclerotic vascular disease. (J Vasc
Surg 2013;57:1331-7.)High demand for blood products has resulted in a fast
increase in transfusion-related costs.1-6 At the same time,
blood transfusion-related morbidity accounts for approxi-
mately 17 billion in medical expenses annually.7 Histori-
cally, the accepted clinical standard has been to transfuse
patients when the hemoglobin (Hb) level drops below
10.0 gm/dL or the hematocrit falls below 30%. This
“10/30 rule” was ﬁrst proposed by Adams and Lundy inthe Michael E. DeBakey VA Medical Center,a and Baylor College of
edicine.b
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for decades6,8 under the premise that a minimal RBC mass
is critical to avoid adverse cardiac events and death. Inter-
estingly, this theoretical assumption has not been proven
correct in practice, and blood transfusion has even been
shown to be harmful. Large observational studies on this
subject have been published analyzing ﬁndings in patients
after myocardial infarction9-13 and after a variety of noncar-
diac operative interventions,14 but their results have been
conﬂicting. Furthermore, randomized controlled trials15-18
after coronary artery bypass, hip replacement, or in the
context of acute myocardial infarction have indicated that
a conservative strategy with a transfusion trigger at serum
Hb of 8 gm/dL can be as safe as the liberal one that implies
that a transfusion should be given when the serum Hb
drops below 10 gm/dL.
Anemia has been shown to be present in up to 15% of
patients presenting with acute coronary syndrome (ACS)19
and is an important predictor of mortality in patients with
heart failure and ischemic heart disease.20 Ischemic heart
disease is the leading cause of mortality in patients with
atherosclerotic vascular disease (ASVD), accounting for1331
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complication after a ASVD-related vascular intervention.21
Thus, patients with ASVD constitute an ideal initial cohort
to assess the impact of transfusion strategies on cardiac
events and mortality. However, relevant data are scarce.
None of the large randomized controlled trials performed
to date involved patients with peripheral arterial disease
(PAD), and the only relevant study was too small to
produce meaningful ﬁndings.17 In this context, we
designed this study to investigate associations between
nadir postoperative Hb (nHb), blood transfusion, and
outcomes after operations for ASVD.
METHODS
Patient population and data extraction. Using a
retrospective cohort design, charts of consecutive patients
who underwent elective operations for atherosclerotic
vascular occlusive disease in a single institution were
reviewed. We included patients who underwent carotid
endarterectomy, open surgical reconstruction for aorto-
iliac occlusive disease and infrainguinal occlusive disease,
aneurysm repair (either open or endovascular) when this
was associated with aorto-iliac occlusive disease, and
amputations. Patients undergoing endovascular interven-
tions only were excluded as these procedures are related
with substantially less operative stress and blood loss than
their open counterparts. Similarly, dialysis access and
venous interventions were not included. Variables of
interest were collected via review of charts located in the
electronic medical record system. These included demo-
graphics, comorbidities, operative information, baseline
and postoperative laboratory values, and outcomes. Base-
line laboratory values were deﬁned as the most recent value
prior to the day of the operation. Perioperative period was
deﬁned as the time period starting from the day of the
operation and ending on the 30th postoperative day.
Exposures of interest. The objective of the study was
to assess the association between a postoperative nHb less
than 10 gm/dL and postoperative outcomes. The choice
of cutoff point was based on traditional clinical guidelines
and was inﬂuenced by the fact that recent major random-
ized controlled trials on this subject have selected a similar
cutoff as transfusion trigger for randomization pur-
poses.15,16,22 Blood transfusion was documented in units
of packed red blood cells (PRBCs) transfused, intra-
operatively and postoperatively, and was analyzed as
a continuous variable. Since both nHb and units of blood
transfused may change at any time during the perioperative
period, we used in our analysis the value of these predictors
prior to the occurrence of the event of interest. Consider for
instance the hypothetical patient who has received 2 units
PRBCs, develops ACS, and then receives 2 more units
PRBCs at a later time. In modeling the contribution of
blood transfusion as a predictor for ACS, we only take into
consideration the 2 units transfused prior to ACS occurring.
This approach was taken to capture the temporal effect
between predictors and outcomes of interest and avoid bias
introduced by practitioners who might have felt compelledto more aggressively transfuse patients, particularly after
a cardiac event.
Endpoints. The primary outcome was a composite
“any vs none” end point (CE) of perioperative death and
ACS. ACS was deﬁned as (1) the presence of a new
Q wave on electrocardiogram in diabetic patients, (2) the
combination of elevated creatine kinase-MB or troponin I
(at least twice of the upper normal limit) and chest pain, or
(3) the combination of enzyme elevation and T wave
inversion, left bundle branch block, ST segment depression
of at least 1 mm, or new Q waves >40 ms in two contig-
uous leads as per recommendations of the American Heart
Association.23,24 The decision to use the speciﬁc CE was
based on the clinical severity of the individual components,
and the fact that sometime it is difﬁcult to even distinguish
between the two (for instance, the case in which a patient
dies suddenly and it is uncertain whether ACS was the
underlying cause).
Secondary outcomes included respiratory complica-
tions, wound complications, and a CE of midterm death
and ACS. Respiratory complications included pneumonia
(deﬁned clinically with the development of fever and/or
cough, and conﬁrmed radiographically); unplanned re-
intubation; and prolonged ventilatory support (more than
48 hours after completion of the operation). Wound
complications included wound infection (suspected clini-
cally and conﬁrmed with the presence of purulent discharge
on exploration of positive wound culture) and wound
dehiscence (deﬁned as the presence of wound separation
severe enough to justify either local wound care or wound
exploration and formal closure). The time-to-event analysis
for the midterm CE included information collected during
a 2-year follow-up.
Statistical analysis. A propensity score was calculated
as the probability of each patient to have postoperative
nHb greater than 10 gm/dL. To calculate the propensity
score, we ﬁt a logistic regression model with nHb as
a binary dependent variable (cutoff at 10 gm/dL). Predic-
tors of this model included patient and operative character-
istics that were thought to impact transfusion decisions and
are listed in Table I. Propensity score was then included in
the analysis models using the inverse-probability-weighting
approach to adjust for baseline differences.
Primary end point. To analyze the binary composite
outcome, we used a multivariate generalized estimating
equation approach and calculated a distinct exposure effect
for each of the components of the CE.25 The average
component-speciﬁc effect was then calculated and tested
for the null hypothesis that the estimated log-odds equals
zero.25,26 Assessing the impact of each exposure (either
nHb or transfusion) on the individual components of the
end point using this approach minimized bias that could
potentially occur because of different incidence rates of the
individual components. Heterogeneity of treatment effects
was evaluated performing an exposure-by-component
interaction statistical signiﬁcance test with the composite
outcome being the dependent variable as previously
described.25 The model was adjusted for within patient
Table I. Distribution of variables used to calculate the
propensity score between the groups and associated
P value before and after propensity score matching
A, Categorical variables
Group A (%) Group B (%)
P value
before PS
P value
after PS
Aspirin 81 81 .896 .919
Statin 76 77 .768 .905
Plavix 23 12 .000 .936
Insulin 22 10 .000 .976
Beta blocker 69 62 .015 .963
ACE inhibitor 63 54 .004 .944
RCRI: II 33 37 .078 .927
RCRI: III 24 16 .000 .957
RCRI: IV 15 5 .000 .937
HTN 94 89 .006 .939
Hyperlipidemia 81 81 .886 .930
CAD 52 42 .002 .954
Renal history 25 12 .000 .835
DM 51 35 .000 .953
CHF 19 9 .000 .968
COPD 26 28 .371 .989
CVA 18 16 .333 .996
Smoking 86 86 .835 .957
ASA score 2 0 1 Ref Ref
ASA score 3 57 70 .981 .980
ASA score 4 43 30 .980 .980
GETA 77 84 .003 .963
EVAR 17 26 Ref Ref
AI occlusive open 6 6 .091 .982
Amputations 26 9 .000 .966
CEA 9 30 .000 .627
Infrainguinal open 41 27 .000 .988
Open AAA 1 2 .398 .930
B, Continuous variables
Group A:
mean (SD)
Group B:
mean (SD)
P value
before
PS
P value
after
PS
Age 66.2 (8.5) 65.6 (8.3) .294 .891
GFR 71.4 (31.6) 79.7 (25.8) .000 .883
Albumin 3.3 (0.7) 3.6 (0.5) .000 .814
BMI 26.2 (5.3) 26.9 (5.1) .043 .851
Baseline
Hb
- - - -
Operative
time
207.3 (139.5) 173.6 (96.4) .000 .986
Operative
blood loss
324.3 (368.9) 235.3 (265.2) .000 .958
Crystalloids 1786.7 (1191.9) 1782.6 (1023.2) - -
AAA, Abdominal aortic aneurysm; ACE, angiotensin converting enzyme;
AI, aortoiliac; ASA, American Society of Anesthesia; BMI, body mass index;
CAD, coronary artery disease; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DM,
diabetes mellitus; EVAR, endovascular aneurysm repair; GETA, general
endotracheal anesthesia; GFR, glomerular ﬁltration rate; HTN, hyperten-
sion; PS, propensity score matching; RCRI, revised cardiac risk index, SD,
standard deviation.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 5 Kougias et al 1333outcome correlation to reﬂect the fact that some patients
had more than one operation. For the given sample size of
1074 operations, this study had 90% power to detect a 50%
reduction in the rate of the CE (from 15% to 7.5%); 85%power to detect a 50% reduction in the rate of ACS (from
10% to 5%); and 32% power to detect 50% reduction in
mortality (from 5% to 2.5%).
Secondary end points. The binary outcomes of respi-
ratory complications and wound infection were compared
using a random effects logistic regression model to account
for within patient correlation of outcomes. Time-to-event
analysis was performed with Cox proportional hazards
regression, also adjusted for multiplicity of operations on
the same patient using a shared frailty model. Level of
statistical signiﬁcance was set at alpha 0.0125 to account
for the four comparisons performed when assessing the
primary end point (two exposures tested against two indi-
vidual outcomes). All analyses were performed using Stata
IC v. 12.1 (StataCorp, College Station, Tex).
RESULTS
Descriptive statistics. Information was available on
consecutive patients who underwent 1182 operations for
atherosclerotic vascular disease. The analysis cohort that was
used in the ﬁnal analysis included 1074 operations (880
patients), separated into those with postoperative nHb $10
gm/dL (group A, n ¼ 451 operations) and those with post-
operative nHb <10 gm/dL (group B, n ¼ 623 operations).
Predictors included in the calculation of the propensity score
and their relative presence in the two patient groups are listed
in Table I, which indicates uniform distribution of covariates
between the two groups of interest. The mean postoperative
Hb for group Awas 11.4 gm/dL (standard deviation, 1.2) vs
8.9 gm/dL (standard deviation, 0.8) for group B (P< .001).
TransfusionofPRBCswasmore frequent ingroupB(median,
2 units; interquartile range, 0-3) than group A (median,
0 units; interquartile range, 0-1) (P < .001), likely reﬂecting
our tendency to transfuse these patients to a serumHbaround
10 gm/dL.
Primary end point. Univariate analysis demonstrated
no association between nHb $10 gm/dL and the CE
(odds ratio [OR], 0.68; 95% conﬁdence interval [CI],
0.54-1.19; P ¼ .12), whereas the number of units PRBCs
transfused (OR, 1.13; 95% CI, 1.05-1.21; P < .001) was
associated with the CE of death and ACS. On the multivar-
iable model in which each one of these covariates was
adjusted for the presence of the other, nHb $10 gm/dL
was not associated with the CE (OR, 0.62; 95% CI,
0.33-1.14; P ¼ .22). Number of PRBCs transfused
remained associated with the CE even after adjusting for
nHb (OR, 1.11; 95% CI, 1.01-1.22; P ¼ .025). However,
given the adjustment of the signiﬁcance criterion to
account for the effect of multiple comparisons, it is likely
that even this association is due to chance. Analyzing the
nHb as continuous variable in the multivariable model
gave similar results. The test for heterogeneity of treatment
effects was not statistically signiﬁcant (P ¼ .218), indicating
no substantial difference in the effects of the individual
exposures across the components of the CE. An interaction
term between nHb and transfusion was introduced to the
model but was found to be non-signiﬁcant statistically
(P ¼ .312), indicating that the impact of transfusion on
Fig 1. Predicted probability for the composite outcome of
perioperative death, cardiac events, and stroke, as a function of
number of packed red blood cells (PRBCs) transfused. The blue
dots indicate patients with nHb <10 gm/dL, whereas the red
dotted line those with nadir hemoglobin (nHb) $10 gm/dL.
Table II. Results of the adjusted bivariate analysis for the
individual outcomes that comprised the primary CE
Predictor OR 95% CI P value
Outcome: perioperative ACS
nHb 0.61 0.33-1.12 .124
Units PRBCs 1.13 1.01-1.27 .031
Outcome: perioperative death
nHb 0.81 0.31-2.62 .549
Units PRBCs 1.12 0.91-1.41 .262
ACS, Acute coronary syndrome; CE, composite end point; CI, conﬁdence
interval; nHb, nadir hemoglobin; OR, odds ratio; PRBCs, packed red blood
cells.
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operative nHb. Fig 1 demonstrates the predicted proba-
bility of the CE occurring at a range of units of blood
transfused and for each level of the postoperative nHb. The
multivariable analysis of associations between nHb, units of
PRBCs, and each of the individual outcomes that
comprised the CE is given in Table II.
Respiratory complications. In univariate analysis
nHb $10 gm/dL (OR, 0.21; 95% CI, 0.09-0.85;
P ¼ .007) and number of PRBCs units transfused (OR,
1.29; 95% CI, 1.10-1.53; P ¼ .006) were both associated
with adverse respiratory events. In the multivariable
adjusted model, however, nHb was no longer a statistically
signiﬁcant predictor (OR, 0.31; 95% CI, 0.09-1.21;
P ¼ .13); whereas the association between units transfused
and adverse respiratory events persisted (OR, 1.22; 95%
CI, 1.04-1.45; P ¼ .009).
Wound complications. Transfusion had no impact
on would complications in either univariate (OR, 1.07;
95% CI, 0.97-1.19; P ¼ .28) or multivariable analysis
(OR, 0.99; 95% CI, 0.90-1.09; P ¼ .93). Maintaining
nHb $10 gm/dL was associated with lower rate of
perioperative wound complications in both univariate
(OR, 0.48; 95% CI, 0.34-0.69; P< .001) and multivariable
analysis (OR, 0.65; 95% CI, 0.4-0.93; P ¼ .01).
Impact on midterm CE of death and ACS. We
examined associations between nHb, blood transfusion
and a composite of mortality and ACS during a 2-year
follow-up. There was no association between nHb and
the CE of death and ACS in either univariate (hazard ratio
[HR], 0.71; 95% CI, 0.42-1.21; P ¼ .21) or multivariable
adjusted analysis (HR, 0.78; 95% CI, 0.45-1.35; P ¼ .373).
Blood transfusion was associated with the CE in both
univariate (HR, 1.20; 95% CI, 1.09-1.34; P < .001) and
bivariate adjusted analysis (HR, 1.15; 95% CI, 1.03-1.29;
P ¼ .009). Given the well-known impact of perioperative
cardiac events on mid- and long-term mortality, we
adjusted our Cox regression model even further by intro-
ducing a binary indicator variable for the presence of
perioperative ACS or cardiac arrest. As anticipated, peri-
operative cardiac events were strongly associated with the
CE (HR, 2.47; 95% CI, 1.32-5.41; P ¼ .008). After
adjusting for the presence of perioperative cardiac events,
the association between transfusion and midterm outcome
persisted (HR, 1.18; 95% CI, 1.04-1.30; P ¼ .007). Fig 2
presents the Kaplan-Meier estimates of composite event at
different levels of blood transfusion.
We also analyzed the impact of nHb, units of blood
transfusion and perioperative cardiac events on the indi-
vidual end points that comprised the composite outcome.
In the multivariable model that included nHb, number
of units PRBCs transfused and perioperative cardiac events
as predictors, nHb had no impact on either midterm
mortality (HR, 0.66; 95% CI, 0.33-1.32; P ¼ .247) or
ACS (HR, 0.89; 95% CI, 0.57-1.30; P ¼ .31). There
was a trend for association between blood transfusion
and mortality (HR, 1.12; 95% CI, 1.02-1.34; P ¼ .02),
as well as between transfusion and ACS (HR, 1.45; 95%CI, 1.2-4.21; P ¼ .025). Perioperative cardiac events
were associated with midterm mortality (HR, 2.69; 95%
CI, 1.12-6.39; P ¼ .009) but not midterm ACS. Figs 3
and 4 demonstrate Kaplan-Meier estimates of the indi-
vidual end points of death and ACS at different levels of
blood transfusion.
DISCUSSION
In this retrospective observational study, we used
propensity score adjustment to analyze the impact of nadir
postoperative Hb and blood transfusion on outcomes after
open operations for ASVD. We showed that nHb levels
below 10 gm/dL can be well tolerated and that there is
a weak association between transfusion and a CE of perio-
perative death and cardiac events. We also showed that
there is an association between perioperative blood transfu-
sion and a composite of death and ACS during a 2-year
follow-up. Those ﬁndings are of importance in health
care practitioners treating patients with ASVD.
The topic of transfusion threshold has been of relatively
strong interest in a variety of settings; however, observa-
tional studies on this subject have produced conﬂicting
Fig 2. Kaplan-Meier estimates for freedom from the midterm
composite end point (CE) of death and acute coronary syndrome
(ACS) during the 2-year follow-up. PRBCs, Packed red blood
cells.
Fig 3. Kaplan-Meier estimates for survival during the 2-year
follow-up. ACS, Acute coronary syndrome; PRBCs, packed red
blood cells.
Fig 4. Kaplan-Meier estimates for freedom from acute coro-
nary syndrome (ACS) during the 2-year follow-up. PRBCs,
Packed red blood cells.
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sions include those by Sabatine11 who performed a post-
hoc analysis of patients enrolled in clinical trials for acute
coronary syndrome, and indicated that baseline anemia
increases the risk for cardiovascular mortality and ischemic
cardiac events. Similarly, Aronson9 demonstrated a protec-
tive effect of transfusion in patients admitted with ACS
who had nadir Hb levels less than 8 gm/dL during their
hospital stay. Wu14 studied perioperative mortality in
veterans who underwent a variety of surgical procedures,
and also suggested a progressive increase of mortality and
cardiac morbidity with declining preoperative Hb mass,
a ﬁnding conﬁrmed later by Musallam in non-veteran
patient population.27 And Foss showed that in patients
undergoing elective hip replacement procedures, a restric-
tive policy with transfusion trigger at serum Hb of
8 gm/dL is associated with increased mortality and cardiacevents.28 Other published studies, however, disagree with
the above ﬁndings. In a post-hoc analysis of a trial29 that
studied the impact of transfusion policy in the intensive
care unit setting, transfusion policy did not impact survival
or incidence of cardiac events in a subset of patients with
known cardiac disease.30 Rao10 showed that transfusion
was associated with increasing mortality rates in patients
who became anemic after they received thrombolytic treat-
ment for acute coronary syndrome, results that persisted
even after correction for the level of nadir Hb level
observed in the patients.
Our study ﬁlls a gap in the literature of transfusion trig-
gers that pertains to the management strategy of patients
with ASVDwho are typically treated as being of high cardiac
risk even in the absence of known coronary artery disease.
This is particularly true when multiple atherosclerotic risk
factors are present. Randomized controlled trials on the
topic of transfusion strategy fall short on assessing patients
at high cardiac risk, but indicate that a conservative transfu-
sion policy is reasonable in critical care setting,2 after coro-
nary artery bypass,16 after acute myocardial infarction,18
and after hip replacement surgery.15 The latter recruited
patients with multiple cardiovascular risk factors but
without formal cardiac risk assessment. In the only available
relevant trial on vascular patients, Bush et al17 found no
difference in the overall complication and mortality rates
between conservative and liberal transfusion groups using
a cutoff Hb 9 gm/dL. Patients who dropped their postop-
erative Hb below that level, however, tended to have more
cardiac complications (14% vs 23%), and the fact that this
difference did not reach statistical signiﬁcance in that study
is likely due to sample-size limitations. Given the paucity of
data for high cardiac risk patients, the recent recommenda-
tions31 from the American Association of Blood Banks
support the notion of a conservative transfusion approach
in patients with pre-existing cardiac disease under a weak
recommendation based on moderate quality evidence.
Since the decisions on blood transfusions are guided by
the physiologic need to provide a critical mass of oxygen
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rupted, a physiologic test would be ideal to assist with clin-
ical decision-making. Unfortunately, such a test has not
been found yet. In fact, several candidate tests or set of tests
have been tried but dismissed as either over-sensitive, or
easily confounded by operation or resuscitation-related
physiologic changes.6 Similarly, clinical indicators of hemo-
dynamic status are often misleading. The lack of sophisti-
cated physiologically driven algorithms led to the
development of the “transfusion trigger” concept, which
dictates that a speciﬁc level of serum Hb can be used to
guide transfusion decisions. This task is deceptively simple,
as it appears that although anemia increases the risk for peri-
operative cardiovascular events and mortality, transfusion
(currently the main treatment that can rapidly correct the
effects of anemia) often fails to provide any beneﬁt and
has been noted to even increase the risk of perioperative
adverse events. This complex interplay was the reason why
we simultaneously analyzed both anemia and transfusion
in a bivariate model to precisely deﬁne their relative contri-
bution to the outcomes of interest. Clearly, a “single
number strategy” oversimpliﬁes the physiologic complex-
ities that underlie blood transfusion and unique circum-
stances, such as prolonged tachycardia, recent cardiac
events, and overall volume status should be taken into
consideration prior to making transfusion decisions.
Our adjusted analysis demonstrated that nHb less than
10 gm/dL can be well tolerated after operations for
ASVD. The association between blood transfusion and
outcomes was more difﬁcult to deﬁne. There was a trend
for increased incidence of the primary end point with
increasing blood transfusions; given the adjustment to
correct for multiple comparisons, however, this did not
reach statistical signiﬁcance. Another complicating factor
in this analysis was the fact that nHb and units of blood trans-
fusion are correlated variables, and the dynamics of their
relationship were difﬁcult to capture in a retrospective study.
It is possible that increasing transfusion needswere related to
lower nHb or a greater physiologic stress of the operation,
but these confounders were not captured objectively
because of the timing of blood sample collection. Therefore,
interpretation of transfusions as having a harmful effect in
the perioperative period should be made with caution.
The association between blood transfusion and the
composite of mortality and ACS during the follow-up
was more clearly deﬁned. Other authors32 have also indi-
cated an unexpected harmful effect for blood transfusion
that is fairly linear, similar to our analysis. This has been
a rather counterintuitive ﬁnding, but it is consistent with
studies that have failed to demonstrate an increase in tissue
oxygenation associated with blood transfusion.33 The
reason for this phenomenon is poorly understood and
may be related to alteration in nitric oxide biology,
decreased 2,3-diphosphoglyceric acid levels, and release
of inﬂammatory mediators.10 Regardless of the underlying
pathophysiologic mechanism and cognizant of the fact that
observational studies like ours are not meant to address
questions of causality, we believe that our ﬁndings whentaken in conjunction with results from major randomized
trials indicate that a conservative transfusion policy is
reasonable in the population we studied.
Limitations of this study are inherent to its retrospec-
tive design. Although propensity score analysis can adjust
for known confounders, unknown covariates that have
a confounding effect may still bias the results. Some impor-
tant variables, such as the presence of intraoperative or
postoperative hypotension or tachycardia, were not avail-
able for analysis. Also, this was a study that included almost
exclusively male patients; as such, our results cannot be
extended to women undergoing the operations under
consideration.
In conclusion, we have shown that nadir postoperative
Hb less than 10 gm/dL is well tolerated after operations
for ASVD and does not increase the risk of a CE of death
and cardiac events. Perioperative transfusion is associated
with a higher rate of a perioperative respiratory complica-
tions and an increased risk of death and ACS during a 2-
year follow-up. Until a randomized controlled trial settles
this issue deﬁnitively, a conservative transfusion approach
is reasonable in male patients undergoing elective operative
intervention for ASVD.AUTHOR CONTRIBUTIONS
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2194-200.Submitted Jun 21, 2012; accepted Oct 17, 2012.DISCUSSIONDr Ronald Fairman (Philadelphia, Pa). My ﬁrst question is,
did you look at the timing of transfusion and did that have an
impact on your results, whether the transfusions were administered
only during the surgery as opposed to the early postoperative or
late postoperative periods?
Dr Panos Kougias. We sure did look at that and it had
a minor impact. The intraoperative transfusion actually had less
of an impact than the postop. But overall, data were collected up
to the point of the event. We tried to avoid the temporal bias
that some observational centers have by collecting data that
included transfusions even after the event of interest had occurred.
So I would say that the postoperative, actually, transfusions were
a more signiﬁcant predictor than the intraoperative.Dr Rabih Chaer (Pittsburgh, Pa). My question really pertains
to the high cardiac risk patient. Your propensity score is as good as
what goes into your model. I brieﬂy looked at the list of the
elements that you included in your analysis, but perhaps the high-
est effect of anemia is dependent on how much it increases myocar-
dial demand. Did you look at whether those patients were beta
blocked or not, because this might impact on the coronary
outcomes of anemia.
DrKougias.Absolutely. Beta blockade, use of statin and,more
interestingly, use of aspirin or Plavix were introduced in the model.
We also included, when we did the propensity score calculation, the
patient’s risk status in terms of revised cardiac risk index. So the
propensity score we had was all adjusted for all those covariates.
